-

Company Profile for bioAffinity Technologies, Inc.

--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories at the University of Texas San Antonio (UTSA). The Company’s platform technology is being developed to diagnose, monitor and treat many cancers.

Company:

bioAffinity Technologies, Inc.

 

 

Headquarters Address:

22211 W I-10, Suite 1206

 

San Antonio, TX 78257

 

 

Main Telephone:

5054009747

 

 

Website:

www.bioaffinitytech.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Maria Zannes

 

 

Public Relations

 

Contact:

Julie Anne Overton

Phone:

5055770918

Email:

jaoverton@mac.com

 

bioAffinity Technologies, Inc.

NASDAQ:BIAF
Details
Headquarters: San Antonio, TX
CEO: Maria Zannes
Employees: 52
Organization: PUB

Release Versions

More News From bioAffinity Technologies, Inc.

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements....

bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

SAN ANTONIO--(BUSINESS WIRE)--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16....

bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment....
Back to Newsroom